VivaCell Biotechnology España

VivaCell Biotechnology is a Spanish biopharmaceutical company specializing in the development of novel cannabinoid-derived small molecules for the treatment of inflammatory and neurodegenerative diseases. Founded as a spin-off from the University of Córdoba, the company focuses on semi-synthetic cannabinoids that target specific pathways such as PPARγ and CB2 receptors without psychotropic effects. Its lead programs, including EHP-101 (formerly VCE-004.8), are being developed for systemic sclerosis and multiple sclerosis. In 2015, VivaCell was acquired by Emerald Health Pharmaceuticals, serving as its primary research and development hub in Europe. The company's proprietary platform enables the creation of new chemical entities that modulate the endocannabinoid system to address high unmet medical needs in rare diseases.